PEOPLE - Scil Biomedical (Germany) makes promotion:

Scil Biomedical (Martinsried, Germany), a developer, manufacturer and marketer of protein based pharmaceuticals and devices, has promoted Thomas Keller to the position of CEO. Mr Keller, who joined the company in January, previously served as vice-president of marketing and sales. He replaces Ulrich Martin, who will continue to act as a consultant.

Scil Biomedical (Martinsried, Germany), a developer, manufacturer and marketer of protein based pharmaceuticals and devices, has promoted Thomas Keller to the position of CEO. Mr Keller, who joined the company in January, previously served as vice-president of marketing and sales. He replaces Ulrich Martin, who will continue to act as a consultant.

More from Archive

More from Medtech Insight

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By 

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By 

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.